Cancer name Glioma
Cancer Type GBMLGG
Immunotherapy type Adoptive Cell Therapy
Treatment Erk1-/- DC
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD8+ T cells
Official Symbol Naive CD8+ T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description While tumor sections demonstrated visibly smaller tumors when treated with BMDC, the number of CD8+ T cells was significantly increased in sections derived from mice treated with WT BMDC compared to PBS-treated groups (1359±39 cells/mm2 and 716±24 cells/mm2, respectively; p=0.001). The infiltration of CD8+ cells was further enhanced when treating mice with Erk1-/- BMDC (1920±49 cells/mm2; p=0.02 when compared to WT BMDC).
PMID 27256374
Title ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas